Evolution of type-specific immunoassays to evaluate the functional immune response to Gardasil®: A vaccine for human papillomavirus types 16, 18, 6 and 11

Human Vaccines

Volumn 4, Issue 2, 2008, Pages 134-142

  Smith, Judith F ^a   Kowalski, Rose ^a   Esser, Mark T ^a   Brown, Martha J ^a   Bryan, Janine T ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Competitive immunoassay; Human papillomavirus; Monoclonal antibody; Neutralizing antibody; Vaccine

Indexed keywords

EPITOPE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY H16.V5; MONOCLONAL ANTIBODY H18.J4; MONOCLONAL ANTIBODY H6.M48; MONOCLONAL ANTIBODY K11.B2; NEUTRALIZING ANTIBODY; WART VIRUS VACCINE;

ANALYZER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; COMPETITIVE INHIBITION; CONFORMATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EVALUATION; FEMALE; HEMAGGLUTINATION INHIBITION; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOASSAY; MOUSE; NONHUMAN; PROCESS DEVELOPMENT; SEROCONVERSION; SERODIAGNOSIS; VERRUCA VULGARIS; VIRUS ATTACHMENT; VIRUS INFECTION; VIRUS LIKE AGENT;

EID: 45849117237     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.4.2.5261     Document Type: Article

References (35)

1. Schiffman M, Castle PE. Human papillomavirus: Epidemiology and public health. Arch Pathol Lab Med 2003; 127:930-4.
2. Clifford GM, Smith JS, Aguado T, Franceschi S. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer; A meta-analysis. Br J Cancer 2003; 89:101-5.
3. Gissmann L, Wolnik L, Ikenberg H, Koldovsky U, Schnürch HG, zur Hausen H. Human papillomavirus types 6 and 11 DNA sequences in genital and laryngeal papillomas and in some cervical cancers. Proc Natl Acad Sci USA 1983; 80:560-3.
4. Clifford GM, Rana RK, Franceschi S, Smith JS, Gough G, Pimenta JM. Human papillomavirus genotype distribution in low-grade cervical lesions: Comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev 2005; 14:1157-64.
5. Cook JC, Joyce JG, George HA, Schultz LD, Hurni WM, Jansen KU, Hepler RW, Ip C, Lowe RS, Keller PM, Lehman ED. Purification of virus-like particles of recombinant human papillomavirus type 11 major capsid protein L1 from Saccharomyces cerevisiae. Protein Expr Purif 1999; 17:477-84.
6. Christensen ND, Kreider JW, Cladel NM, Patrick SD, Welsh PA. Monoclonal antibody-mediated neutralization of infectious human papillomavirus type 11. J Virol 1990; 64:5678-81.
7. Milstein C. With the benefit of hindsight. Immunol Today 2000; 21:359-64.
8. Pastrana DV, Buck CB, Pang YYS, Thompson CD, Castle PE, FitzGerald PC, Krüger Kjaer S, Lowy DR, Schiller JT. Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology 2004; 321:205-16.
9. Roden RBS, Hubbert NL, Kirnbauer R, Christensen ND, Lowy DR, Schiller JT. Assessment of the serological relatedness of genital human papillomaviruses by hemagglutination inhibition. J Virol 1996; 70:3298-301.
10. Stanley M. Immune responses to human papillomavirus. Vaccine 2006; 24:Sl/16-22.
11. Giroglou T, Sapp M, Lane C, Fligge C, Christensen ND, Streeck RE, Rose RC. Immunological analyses of human papillomavirus capsids. Vaccine 2001; 19:1783-93.
12. Dias D, Van Doren J, Schlottmann S, Kelly S, Puchalski D, Ruiz W, Boerckel P, Kessler J, Antonello JM, Green T, Brown M, Smith J, Chirmule N, Barr E, Jansen KU, Esser MT. Optimization and validation of a multiplexed luminex assay to quantify antibodies to neutralizing epitopes on human papillomaviruses 6, 11, 16, and 18. Clin Diagn Lab Immunol 2005; 12:959-69.
13. Christensen ND, Reed CA, Cladel NM, Hall K, Leiserowitz GS. Monoclonal antibodies to HPV-6 L1 virus-like particles identify conformational and linear neutralizing epitopes on HPV-11 in addition to type-specific epitopes on HPV-6. Virology 1996; 224:477-86.
14. Christensen ND, Dillner J, Eklund C, Carter JJ, Wipf GC, Reed CA, Cladel NM, Galloway DA. Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies. Virology 1996; 223:174-84.
15. Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256:495-7.
16. Roden RBS, Hubbert NL, Kirnbauer R, Breitburd F, Lowy DR, Schiller JT. Papillomavirus L1 capsids agglutinate mouse erythrocytes through a proteinaceous receptor. J Virol 1995; 69:5147-51.
17. Yeager MD, Aste-Amezaga M, Brown DR, Martin MM, Shah MJ, Cook JC, Christensen ND, Ackerson C, Lowe RS, Smith JF, Keller P, Jansen KU. Neutralization of human papillomavirus (HPV) pseudovirions: A novel and efficient approach to detect and characterize HPV neutralizing antibodies. Virology 2000; 278:570-7.
18. Palker TJ, Monteiro JM, Martin MM, Kakareka C, Smith JF, Cook JC, Joyce JG, Jansen KU. Antibody, cytokine and cytotoxic T lymphocyte responses in chimpanzees immunized with human papillomavirus virus-like particles. Vaccine 2001; 19:3733-43.
19. Ruiz W, McClements WL, Jansen KU, Esser MT. Kinetics and isotype profile of antibody responses in rhesus macaques induced following vaccination with HPV 6, 11, 16 and 18 L1-virus-like particles formulated with or without Merck aluminum adjuvant. J Immune Based Ther Vaccines 2005; 3:2.
20. Shank-Retzlaff M, Wang F, Morley T, Anderson C, Hamm M, Brown M, Rowland K, Pancari G, Zorman J, Lowe R, Schultz L, Teyral J, Capen R, Oswald CB, Wang Y. Washabaugh M, Jansen K, Sitrin R. Correlation between mouse potency and in vitro relative potency for human papillomavirus type 16 virus-like particles and Gardasil® vaccine samples. Human Vaccines 2005; 1:191-7.
21. O'Connell MA, Belanger BA, Haaland PD. The four parameter logistic model for calibration and assay development. American Statistical Association Proceedings of the Biopharm Section 1992.
22. Opalka D, Lachman CE, MacMullen SA, Jansen KU, Smith JF, Chirmule N, Esser MT. Simultaneous quanritation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16, and 18 by a multiplexed luminex assay. Clin Diagn Lab Immunol 2003; 10:108-15.
23. Christensen ND, Kirnbauer R, Schiller JT, Ghim SJ, Schlegel R, Jenson AB, Kreider JW. Human papillomavirus types 6 and 11 have antigenically distinct strongly immunogenic conformationally dependent neutralizing epitopes. Virology 1994; 205:329-35.
24. Hines JF, Ghim SJ, Christensen ND, Kreider JW, Barnes WA, Schlegel R, Jenson AB. The expressed L1 proteins of HPV-1, HPV-6, and HPV-11 display type-specific epitopes with native conformation and reactivity with neutralizing and nonneutralizing antibodies. Pathobiology 1994; 62:165-71.
25. Smith JF, Brownlow M, Brown MJ, Kowalsk R, Esser MT, Ruiz W, Barr E. Brown DR, Bryan JT. Antibodies from women immunized with Gardasil® cross-neutralize HPV 45 pseudovirions. Human Vaccines 2007; 3:109-15.
26. Christensen ND, Cladel NM, Reed CA Postattachment neutralization of papillomaviruses by monoclonal and polyclonal antibodies. Virology 1995; 207:136-42.
27. Bernard HU. The clinical importance of the nomenclature, evolution and taxonomy of human papillomaviruses. J Clin Virol 2005; 32:Sl-6.
28. de Villiers EM, Fauquer C, Broker TR, Bernard HU, zur Hausen H. Classification of papillomaviruses. Virology 2004; 324:17-27.
29. Koutsky LA, Ault KA, Wheeler CM, Brown DR, Bart E, Alvarez FB, Chiacchierini LM, Jansen KU for the Proof of Principle Study Investigators. A conrrolled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002; 347:1645-51.
30. Ault KA, Giuliano AR, Edwards RP, Tamms G, Kim LL, Smith JF, Jansen KU, Allende M, Taddeo FJ, Skulsky DM. A phase I study to evaluate a human papillomavirus (HPV) type 18 L1 VLP vaccine. Vaccine 2004; 22:3004-7.
31. Fife KH, Wheeler CM, Koutsky LA, Barr E, Brown DR, Schiff MA, Kiviat B, Jansen KU, Barber H, Smith JF, Tadesse A, Giacoletti K, Smith PR, Suhr G, Johnson DA Dose ranging studies of the safety and immunogenicity of human papillomavirus Type 11 and Type 16 viruslike particle candidate vaccines in young healthy women. Vaccine 2004; 22:2943-52.
32. Poland GA, Jacobson RM, Koutsky LA, Tamms GM, Railkar R, Smith JF, Bryan JT, Cavanaugh PF, Jansen KU, Barr E. Immunogenicity and reactogenicity of a novel vaccine for human papillomavirus 16: A 2year randomized controlled clinical trial. Mayo Clinic Proceedings 2005; 80:601-10.
33. Villa LL, Ault KA, Giuliano AR, Costa RLR, Petta CA, Andrade RP, Brown DR, Ferenczy A, Harper DM, Koutsky LA, Kurman RJ, Lehtinen M, Malm C, Olsson SE, Ronnett BM, Skjeldestad FE, Steinwall M, Stoler MH, Wheeler CM, Taddeo FJ, Yu J, Lupinacci L, Railkar R, Marchese R, Esser MT, Bryan J, Jansen KU, Sings HL, Tamms GM, Saah AJ, Barr E. Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. Vaccine 2006; 24:5571-83.
34. Brown DR, Bryan JT, Schroeder JM, Robinson TS, Fife KH, Wheeler CM, Barr E, Smith PR, Chiacchierini L, DiCello A, Jansen KU. Neutralization of human papillomavirus type 11 (HPV-11) by serum from women vaccinated with yeast-derived HPV-11 L1 virus-like particles: Correlation with competitive radioimmunoassay titer. J Infect Dis 2001; 184:1183-6.
35. Mao C, Koutsky LA, Ault KA, Wheeler CM, Brown DR, Wiley DJ, Alvarez FB, Bautista OM, Jansen KU, Barr E. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: A randomized controlled trial. Obstet Gynecol 2006; 107:18-27.